Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 31%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova has shown a positive financial trajectory, with a year-over-year operating margin increase of 180 basis points, driven by enhanced gross margins and effective management of selling, general, and administrative expenses. The company posted mid-single-digit revenue growth of 6.7% for 2024 and anticipates organic growth in the cardiopulmonary segment of 7.0-8.0% for 2025, spurred by the launch of the Essenz HLM and gains in oxygenator market share. Additionally, LivaNova's capacity for oxygenators has been improved by 10% in 2024, with expectations of a further 10-15% increase in capacity for 2025, positioning the company for continued revenue expansion.

Bears say

LivaNova's financial outlook appears negative due to slowing revenue growth in key segments, specifically in Neuromodulation and Cardiopulmonary divisions, where growth rates have significantly decreased compared to prior quarters. The company's recent guidance indicates a potential revenue growth deceleration to low-single digits, which aligns with challenges in the U.S. and international epilepsy markets stemming from personnel changes. Additionally, pressure on operating margins and expectations for below-consensus earnings contribute to concerns regarding overall financial performance.

Livanova (LIVN) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 13 analysts, Livanova (LIVN) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.